CN102127058A - 治疗异常细胞生长的嘧啶衍生物 - Google Patents

治疗异常细胞生长的嘧啶衍生物 Download PDF

Info

Publication number
CN102127058A
CN102127058A CN2011100212904A CN201110021290A CN102127058A CN 102127058 A CN102127058 A CN 102127058A CN 2011100212904 A CN2011100212904 A CN 2011100212904A CN 201110021290 A CN201110021290 A CN 201110021290A CN 102127058 A CN102127058 A CN 102127058A
Authority
CN
China
Prior art keywords
amino
methyl
base
alkyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011100212904A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·卢齐欧
J·C·卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102127058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN102127058A publication Critical patent/CN102127058A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2011100212904A 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物 Pending CN102127058A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
US60/571,312 2004-05-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800155302A Division CN1953974A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Publications (1)

Publication Number Publication Date
CN102127058A true CN102127058A (zh) 2011-07-20

Family

ID=34966230

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011100212904A Pending CN102127058A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物
CNA2005800155302A Pending CN1953974A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800155302A Pending CN1953974A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Country Status (27)

Country Link
EP (1) EP1751143A1 (ko)
JP (1) JP4099212B2 (ko)
KR (1) KR100886990B1 (ko)
CN (2) CN102127058A (ko)
AP (1) AP2241A (ko)
AR (1) AR049097A1 (ko)
AU (2) AU2005243397A1 (ko)
BR (1) BRPI0511138A (ko)
CA (1) CA2566707A1 (ko)
CR (1) CR8749A (ko)
EA (1) EA200601796A1 (ko)
EC (1) ECSP066997A (ko)
GE (1) GEP20104875B (ko)
GT (1) GT200500113A (ko)
IL (1) IL178828A0 (ko)
MA (1) MA28583B1 (ko)
MX (1) MXPA06011890A (ko)
NL (2) NL1029045C2 (ko)
NO (1) NO20064576L (ko)
NZ (1) NZ550448A (ko)
PA (1) PA8632601A1 (ko)
PE (1) PE20060240A1 (ko)
TN (1) TNSN06370A1 (ko)
TW (1) TWI303635B (ko)
UY (1) UY28894A1 (ko)
WO (1) WO2005111023A1 (ko)
ZA (1) ZA200608394B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
JP4332590B2 (ja) * 2005-12-21 2009-09-16 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
CN103951658B (zh) * 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004056786A2 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004056786A2 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EP1751143A1 (en) 2007-02-14
NZ550448A (en) 2010-11-26
GEP20104875B (en) 2010-01-11
PA8632601A1 (es) 2006-06-02
JP4099212B2 (ja) 2008-06-11
CN1953974A (zh) 2007-04-25
IL178828A0 (en) 2007-03-08
MA28583B1 (fr) 2007-05-02
AR049097A1 (es) 2006-06-28
KR20070012477A (ko) 2007-01-25
NL1031845C2 (nl) 2006-11-23
PE20060240A1 (es) 2006-04-01
TNSN06370A1 (fr) 2008-02-22
AP2241A (en) 2011-06-01
TW200539871A (en) 2005-12-16
GT200500113A (es) 2006-01-10
NL1029045C2 (nl) 2006-06-02
KR100886990B1 (ko) 2009-03-04
CR8749A (es) 2006-12-05
BRPI0511138A (pt) 2007-11-27
NO20064576L (no) 2006-11-07
ZA200608394B (en) 2008-05-28
EA200601796A1 (ru) 2007-04-27
UY28894A1 (es) 2005-12-30
WO2005111023A1 (en) 2005-11-24
TWI303635B (en) 2008-12-01
NL1029045A1 (nl) 2005-11-15
MXPA06011890A (es) 2006-12-14
ECSP066997A (es) 2007-02-28
CA2566707A1 (en) 2005-11-24
NL1031845A1 (nl) 2006-07-31
JP2007537234A (ja) 2007-12-20
AU2009238255A1 (en) 2009-12-03
AP2006003790A0 (en) 2006-10-31
AU2005243397A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
CN102127058A (zh) 治疗异常细胞生长的嘧啶衍生物
US7109337B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CN101346380B (zh) 用于治疗异常细胞生长的嘧啶衍生物
EP1625121B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW202115024A (zh) 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
JP5989664B2 (ja) 治療用の化合物および組成物
TW200536833A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP2007537235A (ja) 異常細胞増殖の治療用ピリミジン誘導体
CN101678215A (zh) 用于治疗异常细胞生长的磺酰胺衍生物
WO2017120194A1 (en) Pyridine and pyridimine compounds as pi3k-gamma inhibitors
AU2020337350A1 (en) Triazolopyrimidines as A2A / A2B inhibitors
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158210

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110720

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158210

Country of ref document: HK